Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction

Meibomian gland dysfunction patients will divide into 2 groups. One group will have 0.05% cyclosporine opthalmic emulsion and the other will have non-preservative artificial tear twice daily, compare the result in 3 months.

Inclusion criteria

• Males or females, of legal age of consent
• Patient has a diagnosis of meibomian gland dysfunction with at least 1 symptom as the following; ocular burning, ocular discomfort, and grittiness
• Had a slit-lamp diagnosis of meibomian gland dysfunction based on the presence of one of the following

• meibomian gland inflammation by lid margin or tarsal erythema, bulbar conjunctiva hyperemia, telangiectasia or thickening irregularity of the eyelid margins
• meibomian gland orifice inclusion (plugging) or abnormal of secretion
• Non-invasive tear break up time (NTBUT) with Tear scope Plus(Keeler, Windsor, UK) ≤ 8 seconds
• Ability to follow study instruction and likely to complete all required visits

Exclusion criteria

• Age < 18 years old
• Patients with severe ocular disease from Steven Johnson syndrome burn, limbal deficiency
• Patients used cyclosporine within past 1 year
• Patients used oral cyclosporine or anticholinergic drug within past 2 months
• Patients with HIV or autoimmune disease
• Patients with active ocular infections and patients with a history of herpes keratitis
• Patients with known or suspected hypersensitivity to any of the ingredients in the formula (cyclosporine, glycerin, castor oil, polysorbate 80, carbomer 1342)
• Female patients are pregnant or nursing
• Patients who wear contact lenses